The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
This is a prospective observational study design. A total of 45 patients with newly diagnosed esophageal cancer will be recruited from the Mackay Memorial Hospital. All tests will be performed at baseline (prior to cancer treatment), weekly during treatment, prior to surgery, and one month after surgery. Tests will include demographic data collection, respiratory muscle performance (maximal inspiratory and expiratory pressure tests combined with diaphragmatic surface electromyography, and pulmonary functional test), dyspnea, and the functional exercise test (6-min walk test).Repeated measure ANOVA will be used for analyzing difference of parameters among various time points.
Study Type
OBSERVATIONAL
Enrollment
45
Mackay Memorial Hospital
Taipei, Taiwan
Change of maximal inspiratory pressure (MIP)
Change from baseline MIP at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of diaphragmatic surface electromyography (EMGdi)
Change from baseline EMGdi at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of forced expiratory volume in one second (FEV1)
Change from baseline FEV1 at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of forced vital capacity (FVC)
Change from baseline FVC at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of functional exercise capacity
Change from baseline 6-minute walking distance at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of dyspnea
Change from baseline Modified Borg Dyspnea score at the end of each week's treatment, and 2 weeks after the completion of treatment
Time frame: Baseline, weekly during treatment, and 2 weeks after the completion of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.